MA40538A - Inhibiteurs de l'époxyde hydrolase soluble et utilisations de ceux-ci - Google Patents

Inhibiteurs de l'époxyde hydrolase soluble et utilisations de ceux-ci

Info

Publication number
MA40538A
MA40538A MA040538A MA40538A MA40538A MA 40538 A MA40538 A MA 40538A MA 040538 A MA040538 A MA 040538A MA 40538 A MA40538 A MA 40538A MA 40538 A MA40538 A MA 40538A
Authority
MA
Morocco
Prior art keywords
epoxide hydrolase
soluble epoxide
hydrolase inhibitors
inhibitors
soluble
Prior art date
Application number
MA040538A
Other languages
English (en)
Inventor
Christoph Dumelin
Anthony D Keefe
Ying Zhang
Original Assignee
X Chem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by X Chem Inc filed Critical X Chem Inc
Publication of MA40538A publication Critical patent/MA40538A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA040538A 2014-08-28 2015-08-26 Inhibiteurs de l'époxyde hydrolase soluble et utilisations de ceux-ci MA40538A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462043275P 2014-08-28 2014-08-28

Publications (1)

Publication Number Publication Date
MA40538A true MA40538A (fr) 2021-04-07

Family

ID=55400481

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040538A MA40538A (fr) 2014-08-28 2015-08-26 Inhibiteurs de l'époxyde hydrolase soluble et utilisations de ceux-ci

Country Status (8)

Country Link
US (2) US10081616B2 (fr)
EP (1) EP3186228A4 (fr)
JP (1) JP2017525777A (fr)
CN (2) CN111454246A (fr)
AU (2) AU2015306643B2 (fr)
CA (1) CA2958881A1 (fr)
MA (1) MA40538A (fr)
WO (1) WO2016033150A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016033150A1 (fr) * 2014-08-28 2016-03-03 X-Chem, Inc. Inhibiteurs de l'époxyde hydrolase soluble et utilisations de ceux-ci
EP3600266B1 (fr) * 2017-03-30 2022-07-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions pharmaceutiques pour utilisation dans le traitement de la calcification cardio-vasculaire
WO2021127517A1 (fr) * 2019-12-18 2021-06-24 Intra-Cellular Therapies, Inc. Nouvelles utilisations
WO2024105225A1 (fr) 2022-11-18 2024-05-23 Universitat De Barcelona Combinaisons synergiques d'un antagoniste du récepteur sigma 1 (s1r) et d'un inhibiteur d'époxyde hydrolase soluble (sehi) et leur utilisation dans le traitement de la douleur

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3245950A1 (de) * 1981-12-24 1983-07-07 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur herstellung substituierter pyridine
AR037233A1 (es) * 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
US20040067985A1 (en) * 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
CA2637620A1 (fr) * 2006-02-16 2007-08-30 Boehringer Ingelheim International Gmbh Pyridineamides substitues pouvant etre employes en tant qu'inhibiteurs d'epoxyde hydrolase soluble
US20090111791A1 (en) 2006-03-10 2009-04-30 Boehringer Ingelheim International Gmbh Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same
WO2008021849A2 (fr) * 2006-08-09 2008-02-21 Smithkline Beecham Corporation Nouveaux composés comme antagonistes ou agonistes inverses à des récepteurs d'opioïdes
CA2672373C (fr) * 2006-12-19 2011-08-30 Pfizer Products Inc. Derives de la nicotinamide en tant qu'inhibiteurs de h-pgds et leur utilisation dans le traitement de maladies liees aux prostaglandines d2
EP2002834A1 (fr) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryle/hétarylamides en tant que modulateurs du récepteur EP2
US20110039860A1 (en) * 2008-05-07 2011-02-17 Cangming Yang Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
CA2725481A1 (fr) * 2008-06-18 2009-12-23 Pfizer Limited Derives de nicotinamide
TW201010997A (en) * 2008-06-18 2010-03-16 Pfizer Ltd Nicotinamide derivatives
EP2149552A1 (fr) * 2008-07-30 2010-02-03 Bayer Schering Pharma AG Dérivés de benzamide 5,6 substitués en tant que modulateurs du récepteur EP2
EP2149551A1 (fr) * 2008-07-30 2010-02-03 Bayer Schering Pharma AG Dérivés de N-(indol-3-ylalkyl)-(hétéro)arylamide en tant que modulateurs du récepteur EP2
US20100113512A1 (en) * 2008-10-30 2010-05-06 Diane Michele Ignar Method of treatment using novel antagonists or inverse agonists at opioid receptors
WO2010080183A1 (fr) * 2009-01-08 2010-07-15 The Trustees Of Columbia University In The City Of New York Inhibiteurs non uréiques efficaces de l'époxyde hydrolase soluble
WO2011091410A1 (fr) * 2010-01-25 2011-07-28 Glaxos Smithkline Llc Antagonistes de trpv4
US20130102601A1 (en) * 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
US20130102600A1 (en) * 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
US8809552B2 (en) * 2011-11-01 2014-08-19 Hoffmann-La Roche Inc. Azetidine compounds, compositions and methods of use
CN104136028A (zh) * 2012-01-25 2014-11-05 纽约市哥伦比亚大学理事会 高效可溶性环氧化物水解酶非脲抑制剂
AU2013347232A1 (en) * 2012-11-16 2015-07-02 Merck Patent Gmbh 3-aminocyclopentane carboxamide derivatives
CN104016914B (zh) * 2014-05-27 2016-03-30 苏州科技学院 一种酰胺化合物的制备方法
WO2016033150A1 (fr) * 2014-08-28 2016-03-03 X-Chem, Inc. Inhibiteurs de l'époxyde hydrolase soluble et utilisations de ceux-ci

Also Published As

Publication number Publication date
WO2016033150A1 (fr) 2016-03-03
JP2017525777A (ja) 2017-09-07
CN111454246A (zh) 2020-07-28
EP3186228A4 (fr) 2018-04-18
US20180362499A1 (en) 2018-12-20
CA2958881A1 (fr) 2016-03-03
CN107074771B (zh) 2020-03-20
EP3186228A1 (fr) 2017-07-05
US10081616B2 (en) 2018-09-25
US20170240526A1 (en) 2017-08-24
AU2015306643B2 (en) 2020-05-07
AU2015306643A1 (en) 2017-03-16
AU2020207828A1 (en) 2020-08-13
CN107074771A (zh) 2017-08-18

Similar Documents

Publication Publication Date Title
DK3129023T3 (da) Potente opløselige epoxidhydrolase-inhibitorer
IL256369A (en) Novel crispr enzymes and systems
EP3471727A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
EP3600273A4 (fr) Inhibiteurs de cd73 et leurs utilisations
EP3472129A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
MA44262A (fr) Bioconjugués et utilisations de ceux-ci
IL280863A (en) Autotaxin inhibitors and uses thereof
EP3389658A4 (fr) Inhibiteurs de glycosidase et leurs utilisations
EP3445365A4 (fr) Inhibiteurs d'ezh2 et leurs utilisations
EP3317273A4 (fr) Inhibiteurs d'egfr et méthodes d'utilisation de ceux-ci
MA46700A (fr) Variants polypeptidiques et ses utilisations
EP3334706A4 (fr) Pillararènes et utilisations de ceux-ci
PT3221363T (pt) Anticorpos contra cd73 e utilizações dos mesmos
EP3332008A4 (fr) Modification du gène de la dystrophine et ses utilisations
EP3344624A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
EP3356416A4 (fr) Anticorps anti-pd-1 et ses utilisations
MA40595A (fr) Récepteurs chimériques et utilisations de ceux-ci en thérapie immunitaire
EP3341387A4 (fr) Inhibiteurs de sialyltransférase et utilisations de ceux-ci
EP3471726A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
PT3319612T (pt) Oxisteróis e métodos de utilização dos mesmos
EP3426244A4 (fr) Inhibiteurs de la 3-phosphoglycérate déshydrogénase et leurs utilisations
DK3194564T3 (da) Trichodermasammensætninger og anvendelsesfremgangsmåder
EP3411391A4 (fr) Variants d' ubiquitin et ses utilisations comme inhibiteurs 53bp1
EP3426243A4 (fr) Inhibiteurs de la 3-phosphoglycérate déshydrogénase et leurs utilisations
MA41022A (fr) Ciblage lysosomial et utilisations correspondantes